Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Sell
50
ZLAB Quote, Financials, Valuation and Earnings
Last price:
$26.60
Seasonality move
:
-2.11%
Day range:
$26.52 - $27.46
52-week range:
$13.48 - $36.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.46x
P/B ratio:
4.38x
Volume:
254.5K
Avg. volume:
1M
1-year change:
5.42%
Market cap:
$2.9B
Revenue:
$266.7M
EPS (TTM):
-$2.70
Analysts' Opinion
-
Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $52.39, Zai Lab has an estimated upside of 92.48% from its current price of $27.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $27.22.
Fair Value
-
According to the consensus of 8 analysts, Zai Lab has 92.48% upside to fair value with a price target of $52.39 per share.
ZLAB vs. S&P 500
-
Over the past 5 trading days, Zai Lab has overperformed the S&P 500 by 2.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Zai Lab does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zai Lab has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Zai Lab reported revenues of $102.3M.
Earnings Growth
-
Zai Lab has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Zai Lab reported earnings per share of -$0.40.
Enterprise value:
2.4B
EV / Invested capital:
3.10x
Price / LTM sales:
7.46x
EV / EBIT:
--
EV / Revenue:
6.81x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.08x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$224.7M
Return On Assets:
-26.86%
Net Income Margin (TTM):
-76.14%
Return On Equity:
-35.53%
Return On Invested Capital:
-33.5%
Operating Margin:
-62.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $196.6M | $263.5M | $355.7M | $69.2M | $102.3M | |
| Gross Profit | $121.8M | $172M | $224.7M | $43.7M | $65.3M | |
| Operating Income | -$522.1M | -$337.7M | -$332.1M | -$82.9M | -$64M | |
| EBITDA | -$514.2M | -$316.3M | -$297.7M | -$67.2M | -$38.1M | |
| Diluted EPS | -$6.30 | -$3.10 | -$2.70 | -$0.70 | -$0.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $1.6B | $1.2B | $959.7M | $860.5M | |
| Total Assets | -- | $1.7B | $1.3B | $1B | $985.3M | |
| Current Liabilities | -- | $112M | $155.5M | $124.9M | $286.3M | |
| Total Liabilities | -- | $140.1M | $192.6M | $162.7M | $317.7M | |
| Total Equity | -- | $1.6B | $1.1B | $881M | $667.7M | |
| Total Debt | -- | -- | -- | -- | $113M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$411.3M | -$292.6M | -$174M | -$55.3M | -$26.8M | |
| Cash From Investing | $142.9M | -$29.6M | -$13M | -$14M | -$29.9M | |
| Cash From Financing | -$1.8M | -$7M | $112.5M | -$1.4M | $42.2M | |
| Free Cash Flow | -$438.4M | -$304.6M | -$218.6M | -$57.1M | -$56.7M | |
ZLAB
Sector
Market Cap
$2.9B
$46.5M
Price % of 52-Week High
74.37%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
5.42%
-31.38%
Beta (5-Year)
0.989
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$26.62
200-day SMA
Buy
Level
$21.09
Bollinger Bands (100)
Buy
Level
19.72 - 29.14
Chaikin Money Flow
Sell
Level
-5.5M
20-day SMA
Sell
Level
$27.52
Relative Strength Index (RSI14)
Sell
Level
49.41
ADX Line
Buy
Level
20.89
Williams %R
Neutral
Level
-63.7019
50-day SMA
Sell
Level
$28.36
MACD (12, 26)
Sell
Level
-0.35
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
2.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.5901)
Sell
CA Score
(Annual)
Level (-0.4161)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.394)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Stock Forecast FAQ
In the current month, ZLAB has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZLAB average analyst price target in the past 3 months is $52.39.
-
Where Will Zai Lab Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zai Lab share price will rise to $52.39 per share over the next 12 months.
-
What Do Analysts Say About Zai Lab?
Analysts are divided on their view about Zai Lab share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zai Lab is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Zai Lab's Price Target?
The price target for Zai Lab over the next 1-year time period is forecast to be $52.39 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZLAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zai Lab is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ZLAB?
You can purchase shares of Zai Lab via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zai Lab shares.
-
What Is The Zai Lab Share Price Today?
Zai Lab was last trading at $26.60 per share. This represents the most recent stock quote for Zai Lab. Yesterday, Zai Lab closed at $27.22 per share.
-
How To Buy Zai Lab Stock Online?
In order to purchase Zai Lab stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 3.22% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 4.72% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.82% over the past day.
